Christopher Martin

Christopher Martin serves as a member of our board of directors and has over 25 years of commercial experience in the biopharma space including marketing, sales, commercial operations, market access, trade and business development.  Mr. Martin most recently served as the Chief Commercial Officer at Verona Pharma, a biopharmaceutical company focused on respiratory diseases which was acquired by Merck & Co in October 2025 for approximately $10 billion.  As CCO, Mr. Martin was responsible for building the commercial organization and launch strategy for the company’s first product launch, Ohtuvayre® (ensifentrine). Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for CNS conditions. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI® (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company’s first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan® marketing team during the company’s acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University.